Skip to main content

View Resource

Published

Nirmatrelvir–ritonavir versus usual care in at-risk adults with early SARS-CoV-2 infection in the UK, 2022–23: virological and immunological results of an open-label randomised trial (PANORAMIC).
Lowe DM. The Lancet Microbe 2026;:https://doi.org/10.1016/j.lanmic.2026.101360.
[Nirmatrelvir–ritonavir is widely used for COVID-19, but effectiveness was established in unvaccinated people with SARS-CoV-2 variants before omicron. Nirmatrelvir–ritonavir is effectively antiviral against omicron SARS-CoV-2 variants, but the magnitude of viral load reduction might be limited by effective population-wide immunity in the immunocompetent population.]
Freely available online
Age Groups
Adults
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Hospital Ward
Intensive Care
Staff Groups
Drug Therapy
Medic